Search alternatives:
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
reported decrease » reported disease (Expand Search), reported depressive (Expand Search), reported case (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
Showing 1 - 20 results of 2,520 for search '(( significantly reported decrease ) OR ( significant ((gap decrease) OR (nn decrease)) ))', query time: 0.60s Refine Results
  1. 1
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  2. 2
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  3. 3
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  4. 4
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 5
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 6
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 7
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 8
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and heart rate (HR) across the three conditions.

    Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... by Robert Trybulski (10998702)

    Published 2025
    Save to List
    Saved in:
  10. 10
    DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb.

    DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

    Published 2025
    Save to List
    Saved in:
  11. 11
    S8 File -

    S8 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 12
    Study populations of included studies.

    Study populations of included studies. by Martha R. Smith (20410184)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 13
    Future research directions.

    Future research directions. by Martha R. Smith (20410184)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 14
    PRISMA flow diagram.

    PRISMA flow diagram. by Martha R. Smith (20410184)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 15
    S9 File -

    S9 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 16
    S7 File -

    S7 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 17
    Participant characteristics of included studies.

    Participant characteristics of included studies. by Martha R. Smith (20410184)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 18
    Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments.

    Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

    Published 2025
    Save to List
    Saved in:
  19. 19
    Inotodiol decreases clone formation in HCC cells.

    Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

    Published 2025
    “…Several studies have reported anticancer effects of inotodiol. This study focuses on the anticancer effect of inotodiol in HCC cells and its molecular mechanism, aiming to explore its anticancer effect in depth. …”
    Save to List
    Saved in:
  20. 20
    Inotodiol decreases clone formation in HCC cells.

    Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

    Published 2025
    Save to List
    Saved in:

Search Tools: